Posted: June 2017 Prof. Nir Peled was elected Head of the European Respiratory Society Thoracic Oncology Assembly. Prof. Peled is a pulmonologist and medical oncologist. He is the head of the […] Read more
Steven M. Keller, MD
Posted: June 2017 Steven M. Keller has been appointed Senior Principal Scientist, Oncology Clinical Research, at Merck, Kenilworth, US. Previous to this appointment, Dr. Keller was Director, Thoracic Surgery, Weiler Hospital; […] Read more
Posted: June 2017 Robert J. Cerfolio has been appointed chief of clinical thoracic surgery at NYU Langone Medical Center, New York, US. Dr. Cerfolio also will serve as director of the […] Read more
Posted: June 2017 By Kimberly Rohan, ANP-BC Treatment for patients with NSCLC today has become increasingly personalized over the past few years. It is paramount to be able to test […] Read more
ELCC 2017 Unveils New Research Regarding Screening, Immunotherapy, Treatment Planning, and More
Posted: June 2017 By Keightley Amen, BA, ELS In early May, at the seventh annual European Lung Cancer Conference (ELCC) in Geneva, Switzerland, multidisciplinary lung cancer professionals gathered to learn […] Read more
Posted: June 2017 By David Planchard, MD, PhD What was the rationale for conducting clinical research in BRAF mutationpositive NSCLC? Recently, progress has been made in characterization of the oncogenic […] Read more
Posted: June 2017 Despite very encouraging progress in the development and use of immunotherapy for patients with non-small cell lung cancer, much confusion remains regarding patient selection for each therapy. […] Read more
Posted: June 2017 For the past 40 years the International Association for the Study of Lung Cancer has remained the only society exclusively dedicated to the study and treatment of […] Read more
Posted: June 2017 NCI to Team Up with Cancer Research UK and the Cancer Research Technology Pioneer Fund on RAS Research On April 19, 2017, Cancer Research UK (CRUK) and […] Read more
• Pembrolizumab (Keytruda) received FDA approval for use in combination with pemetrexed and carboplatin for the first-line treatment of patients with metastatic nonsquamous NSCLC, irrespective of PD-L1 expression. This approval […] Read more